5: List of resources to be considered in the economic analysis Number of Disaggregated unit cost units of resource per relevant Provider of Setting in Proportion time resource MBS Patient which of patients Other Private horizon per Safety Total resource is receiving govt health patient nets* cost provided resource budget insurer receiving resource Resources provided to deliver proposed intervention: EGFR gene mutation testing and treatment with either first-line erlotinib or platinum-based doublet chemotherapy Resources associated with introduction of EGFR test Block retrieval of Pathologist TBD (not all 1 ‐ stored sample from samples will tissue archive (from need to be most recent biopsy) retrieved if biopsy performed at diagnosis of metastatic disease) Biopsy (where Respiratory Hospital Approx 10% ‐ there is an oncologist patient unsuitable sample form tissue archive) Pathologist 100% of pts 1 Preparation of ‐ tissue sample eligible for treatment Perform the EGFR Molecular 100% of pts 1 ~$400 ‐ test pathologist eligible for treatment Analysis and Molecular 100% of pts 1 ‐ reporting on result pathologist eligible for EGFR status treatment ‐ determined from tumour biopsy and/or tissue markers for prognostic tissue If EGFR positive, patient is eligible for treatment with erlotinib Specialist Medical 14.2% of all TBD $72.65 ‐ oncologist patients who consultation for initiation in erlotinib have an (oral tablet) EGFR gene (MBS 116) mutation (EURTAC (Rosell R et al 2011) Cost of erlotinib (30 14.2% of TBD $3309.66 ‐ patients tabs x 150mg) (PBS cost per maximum quantity) If EGFR negative patients receives platinum doublet chemotherapy Specialist Medical ~90% TBD $72.65 ‐ consultation for oncologist (EGFR negative initiation in chemotherapy pts) (MBS 116) Cost of ~10% TBD $265.32 ‐ chemotherapy (1 x (EGFR negative 45mg carboplatin) (PBS cost per pts) maximum quantity) Cost of ~90% TBD $890.78 ‐
5: List of resources to be considered in the economic analysis Provider of resource Setting in which resource is provided Proportion of patients receiving resource Number of units of resource per relevant time horizon per patient receiving resource Disaggregated unit cost MBS Safety nets* Other govt budget Private health insurer Patient Total cost Resources provided to deliver proposed intervention: EGFR gene mutation testing and treatment with either first-line erlotinib or platinum-based doublet chemotherapy Resources associated with introduction of EGFR test ‐ Block retrieval of stored sample from tissue archive (from most recent biopsy) Pathologist TBD (not all samples will need to be retrieved if biopsy performed at diagnosis of metastatic disease) 1 ‐ Biopsy (where there is an unsuitable sample form tissue archive) Respiratory oncologist Hospital patient Approx 10% ‐ Preparation of tissue sample Pathologist 100% of pts eligible for treatment 1 ‐ Perform the EGFR test Molecular pathologist 100% of pts eligible for treatment 1 ~$400 ‐ Analysis and reporting on result ‐ EGFR status determined from tumour biopsy and/or tissue markers for prognostic tissue Molecular pathologist 100% of pts eligible for treatment 1 If EGFR positive, patient is eligible for treatment with erlotinib ‐ Specialist consultation for initiation in erlotinib (oral tablet) (MBS 116) Medical oncologist 14.2% of all patients who have an EGFR gene mutation (EURTAC (Rosell R et al 2011) TBD $72.65 ‐ Cost of erlotinib (30 tabs x 150mg) (PBS cost per maximum quantity) 14.2% of patients TBD $3309.66 If EGFR negative patients receives platinum doublet chemotherapy ‐ Specialist consultation for initiation in chemotherapy (MBS 116) Medical oncologist ~90% (EGFR negative pts) TBD $72.65 ‐ Cost of chemotherapy (1 x 45mg carboplatin) (PBS cost per maximum quantity) ~10% (EGFR negative pts) TBD $265.32 ‐ Cost of ~90% TBD $890.78
1173-Final-DAP-EGFR-for-erlotinib-accessibleFINAL.docx